At the bulk level, we find an upregulation of lipid metabolism pathways, consistent with previous findings that positive effects of LXR agonists on AD pathology in preclinical models are largely due to the induction of ABCA1 expression, which promotes cholesterol clearance and APOE lipidation17,53. The gene discussed is ABCA1; the disease is Alzheimer disease.